-
Dec 9, 2024 | 
hcplive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
OpinionVideoDecember 9, 2024Author(s):, Early-stage CKD management emphasizes lifestyle changes, blood pressure, and glycemic control to slow disease progression. Advanced CKD treatment involves intensive interventions like dialysis or transplantation, tailored to individual patient needs. Nonsteroidal MRAs, such as finerenone, block mineralocorticoid receptors, reducing kidney inflammation and fibrosis.
-
Dec 9, 2024 | 
consultantlive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
Integration of Cardiovascular Care Into CKD ManagementPublished on: December 9, 2024Rajiv Agarwal, MD, Mark A. Meeker, DO, FACP, CPE , Martha Gulati, MD, Susanne B. Nicholas, MD, MPH, PhDPanelists discuss the role of cardiovascular risk management for patients with chronic kidney disease (CKD) and how cardiovascular care can be effectively integrated into CKD management strategies. What role should cardiovascular risk management play in the treatment for these patients?
-
Dec 9, 2024 | 
hcplive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
OpinionVideoDecember 9, 2024Author(s):, Cardiovascular risk management is essential in CKD treatment due to the high prevalence of cardiovascular complications in this population. Addressing traditional and CKD-specific risk factors is vital for effective cardiovascular risk management. A multidisciplinary approach involving nephrologists, cardiologists, and primary care providers is necessary for integrating cardiovascular care into CKD management.
-
Dec 2, 2024 | 
hcplive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
OpinionVideoDecember 2, 2024Author(s):, Genital mycotic infections on SGLT-2 inhibitors are typically managed with topical antifungals, continuing the inhibitor unless infections are severe or recurrent. Addressing adverse effects of GLP-1 receptor agonists involves discussing therapy benefits, considering dose adjustments, or exploring alternative treatments to maintain efficacy.
-
Dec 2, 2024 | 
hcplive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
OpinionVideoDecember 2, 2024Author(s):, SGLT2 inhibitors reduce glucose reabsorption, providing renal and cardiovascular benefits in CKD management for type 2 diabetes patients. RAAS inhibitors target the renin-angiotensin-aldosterone system, reducing blood pressure and proteinuria, slowing CKD progression. GLP-1 receptor agonists enhance insulin secretion and offer cardiovascular protection, contributing to CKD management.
-
Nov 25, 2024 | 
consultantlive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
Early Detection of CKD in Stages 2 and 3Published on: November 25, 2024Rajiv Agarwal, MD, Mark A. Meeker, DO, FACP, CPE , Martha Gulati, MD, Susanne B. Nicholas, MD, MPH, PhDPanelists discuss how early detection of chronic kidney disease (CKD) in stages 2 and 3 can improve patient outcomes across various specialties, including nephrology, cardiology, and primary care.
-
Nov 25, 2024 | 
hcplive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
OpinionVideoNovember 25, 2024Author(s):, Early CKD detection in nephrology enables interventions to slow progression and preserve renal function, improving patient outcomes. Cardiology benefits from early CKD detection by managing cardiovascular risk factors, reducing cardiovascular event incidence. Primary care providers can coordinate comprehensive care plans, ensuring timely referrals and lifestyle modifications for CKD patients.
-
Nov 25, 2024 | 
hcplive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
OpinionVideoNovember 25, 2024Author(s):, Misinterpretation of test results and lack of awareness contribute to high rates of missed CKD diagnoses, even when tests are conducted. Untreated CKD in type 2 diabetes patients can lead to kidney damage progression, increased cardiovascular risk, and higher mortality. Cardiologists often prioritize cardiovascular issues, while primary care providers may struggle with managing multiple comorbidities, leading to CKD under-treatment.
-
Nov 18, 2024 | 
hcplive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
OpinionVideoNovember 18, 2024Author(s):, Limited awareness and lack of standardized protocols hinder uACR testing, necessitating enhanced provider education and patient awareness initiatives. A multimodal approach, including lifestyle changes and pharmacotherapy, is crucial for achieving guideline goals in reducing uACR. Early detection through increased CKD testing awareness can significantly improve patient outcomes by enabling timely interventions.
-
Nov 18, 2024 | 
consultantlive.com | Rajiv Agarwal |Mark Meeker |Martha Gulati |Susanne B. Nicholas
Key Updates in Clinical Guidelines for CKD Testing in Patients With Type 2 Diabetes Published on: November 18, 2024Rajiv Agarwal, MD, Mark A. Meeker, DO, FACP, CPE , Martha Gulati, MD, Susanne B. Nicholas, MD, MPH, PhDPanelists discuss key updates in clinical guidelines for chronic kidney disease (CKD) testing in patients with type 2 diabetes, highlighting the latest recommendations for improving screening and diagnosis.
